Grifols Successfully Enrolls Targeted Number of Patients in Phase 3 Study of Prolastin®-C for Emphysema Due to Alpha-1-Antitrypsin Deficiency
Grifols, a global leader in plasma-derived medicines, has achieved its enrollment goal of 339 patients for the SPARTA clinical trial. This groundbreaking study aims to assess the effectiveness and safety of two different weekly doses of Grifols' Prolastin®-C in slowing down the progression of emphysema in individuals with alpha-1 antitrypsin (AAT) deficiency. AAT deficiency is a genetic factor that increases the risk of developing chronic obstructive pulmonary disease (COPD), including emphysema, which is a leading cause of mortality worldwide.